SLC5A2 and chronic kidney disease: More recently, treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists—and most recent with SGLT2 inhibitors in combination with non-steroid mineralocorticoid antagonists—has demonstrated beneficial effects in delaying CKD progression, and reducing cardiovascular events and mortality.29, 30, 31, 32 However, these pharmacological treatments remain underutilised despite their proven benefits.